Abstract Body

Background:

The monkeypox epidemic in the UK began in May 2022. Unexpectedly and rapidly, rates of new cases declined during August 2022. Identifying the causes of this decline requires accurate estimates of the time-varying epidemic growth rate, which in turn depend upon the delay between symptom onset to healthcare presentation. In this paper, we utilise modelling and monkeypox data from the UK to quantify the changes in this delay and their effect on estimating the epidemic growth rate of monkeypox over the period May-August 2022 in the UK.

Methods:

We developed a custom nowcasting Bayesian method which incorporates time-varying delays (EpiLine), simulating the growth rate of symptomatic cases and the parameters of delay distributions following Gaussian processes. We applied our model to the monkeypox data from the UK, sampling the posterior distribution of all parameters using Markov Chain Monte Carlo methods, to quantify the delay between monkeypox symptom onset to healthcare presentation and the growth rate over the study period.

Results:

Our results suggest that the delay between symptom onset and healthcare presentation for monkeypox in the UK decreased from an average of 22 days in early May 2022 to 10 days by early June and 7 days in August 2022. When we account for these dynamic delays, the time-varying growth rate declined gradually in the UK over the May-September 2022 period. Not accounting for varying time delays would have incorrectly characterised the growth rate by a sharp increase followed by a rapid decline in monkeypox cases.

Conclusions:

Our results highlight the importance of correctly quantifying the delay between symptom onset to healthcare presentation when charactering the epidemic growth of monkeypox in the UK. We show that reducing the delay in accessing healthcare is crucial as shorter delays can prevent onwards transmission, and allows prompt use of antivirals post infection. Hence, our study highlights the importance and need for public health agencies to focus on reducing delays from symptom onset to healthcare presentation early in an outbreak and when tailoring the optimal policy response.